DLA Piper advises AN Venture Partners in Tortugas Neuroscience’s US$75.5 million Series A financing

DLA Piper advised AN Venture Partners, a venture capital firm, in the US$75.5 million Series A financing of Tortugas Neuroscience, Inc., a neurology-focused biotech company.

Tortugas Neuroscience launched with US$106 million in seed and Series A financings to advance a clinical-stage pipeline targeting major neurology and neuropsychiatric disorders, including schizophrenia, tinnitus, and focal epilepsy, among other high, unmet need central nervous system indications. The funding will support ongoing research and development initiatives, including the completion of Phase 2 clinical trials for its two lead candidates.

The deal team was led by Partner Josh Seidenfeld (Palo Alto), who leads the firm’s Northern California Corporate and Securities practice, and included Partners Christine Daya (Washington, DC), Lauren Murdza (Philadelphia), Yoni Tuchman (Los Angeles), and Christina Houston (Wilmington), as well as Associates Andrew Dietrick (Philadelphia), Matthew Larson (Washington, DC), and Thomas Heiser (Miami).

DLA Piper’s Emerging Growth and Venture Capital practice includes more than 200 lawyers who provide strategic counsel to emerging companies and venture capital firms in high-growth industries, including technology, healthcare, life sciences, and financial services. Over the last three years, DLA Piper has completed more than 2,100 financings globally, totaling more than US$80 billion. The firm is ranked among the most active global law firms for venture capital deal volume, according to PitchBook.